These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15897249)

  • 41. Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
    Miki T; Nonomura N; Takaha N; Nishimura K; Kojima Y; Sawada M; Okuyama A
    Int J Urol; 1998 Jul; 5(4):370-3. PubMed ID: 9712447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polymer chemotherapy for head and neck cancer.
    Shikani AH; Domb AJ
    Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylselenocysteine resets the rhythmic expression of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo.
    Fang MZ; Zhang X; Zarbl H
    Cancer Prev Res (Phila); 2010 May; 3(5):640-52. PubMed ID: 20424134
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
    Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
    Shimoyama T; Koizumi F; Fukumoto H; Kiura K; Tanimoto M; Saijo N; Nishio K
    Lung Cancer; 2006 Jul; 53(1):13-21. PubMed ID: 16713012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
    Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
    Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
    Kaneko S; Kaneko M; Fukushima T
    Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
    Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
    Maeda Y; Hamada A; Sanematsu E; Sasaki JI; Yokoo K; Hira A; Saito H
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):953-9. PubMed ID: 19697031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
    Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
    Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.